- Home
- BCAB vs UBX Comparison
BCAB vs UBX Comparison
Compare BCAB & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- UBX
- Stock Information
- Founded
- BCAB 2007
- UBX 2009
- Country
- BCAB United States
- UBX United States
- Employees
- BCAB N/A
- UBX N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- UBX Health Care
- Exchange
- BCAB Nasdaq
- UBX Nasdaq
- Market Cap
- BCAB 28.6M
- UBX 29.2M
- IPO Year
- BCAB 2020
- UBX 2018
- Fundamental
- Price
- BCAB $0.46
- UBX $2.22
- Analyst Decision
- BCAB Buy
- UBX Strong Buy
- Analyst Count
- BCAB 2
- UBX 2
- Target Price
- BCAB $5.00
- UBX $7.00
- AVG Volume (30 Days)
- BCAB 990.6K
- UBX 483.8K
- Earning Date
- BCAB 03-25-2025
- UBX 11-04-2024
- Dividend Yield
- BCAB N/A
- UBX N/A
- EPS Growth
- BCAB N/A
- UBX N/A
- EPS
- BCAB N/A
- UBX N/A
- Revenue
- BCAB $11,000,000.00
- UBX N/A
- Revenue This Year
- BCAB N/A
- UBX N/A
- Revenue Next Year
- BCAB N/A
- UBX $33.62
- P/E Ratio
- BCAB N/A
- UBX N/A
- Revenue Growth
- BCAB N/A
- UBX N/A
- 52 Week Low
- BCAB $0.43
- UBX $0.94
- 52 Week High
- BCAB $4.02
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- BCAB 23.28
- UBX 61.12
- Support Level
- BCAB $0.46
- UBX $2.02
- Resistance Level
- BCAB $0.49
- UBX $2.42
- Average True Range (ATR)
- BCAB 0.04
- UBX 0.31
- MACD
- BCAB 0.03
- UBX 0.01
- Stochastic Oscillator
- BCAB 27.98
- UBX 39.61
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.